One-line thesis. PepsiCo is a fortress-quality, low-beta consumer staple throwing off ~$7.7B of free cash flow and a ~4% dividend — but FY25 revenue grew only ~2% and GAAP EPS actually fell, the stock is down ~15% from its high while the market ran, and there is no Synthos expert conviction behind it; it is a Watch — own it for income and stability, not for growth.
◆ Synthos call — HoldPEP is a solid business largely reflected at ~$159 — fine to keep, no reason to chase; it gets interesting again below ~$135.
Downside Risk (lower = safer)
4/10 · Moderate
Beta 0.36 & defensive staple, but 2.6× net-debt/EBITDA, ~26% drawdown, GLP-1 & soda secular headwinds.
Growth Quality
5/10 · Moderate
Only ~4% forward core-EPS CAGR, GAAP EPS fell in FY25, margins soft — durable moat but slow.
Exponential Potential
2/10 · Low
Mature $197B mega-cap, growth decelerating to low-single-digits, no room for a multibagger.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 9%/yrTo justify today’s $144, earnings would have to compound roughly 9% a year for 10 years (9% discount rate). Analysts forecast ~6%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
PepsiCo makes the stuff you already know: Pepsi, Gatorade, Mountain Dew, Lay's, Doritos, Cheetos, Quaker oats, and Tropicana. Roughly half the company is snacks and half is drinks, and a bit more than half its sales are in the United States. It is a big, steady, boring cash machine that pays a solid dividend (about 4% a year).
Is the stock cheap or expensive? It's roughly fair — maybe slightly cheap. You are not overpaying, but you are not getting a bargain either. The problem is that the business is barely growing: last year sales crept up only ~2% and profit per share actually went down a little.
Our verdict is Watch — a decent, safe stock to hold for income, but there's no exciting reason to rush in. The single biggest worry is the weight-loss drugs (like Ozempic/Zepbound) and the general health shift slowly pushing people away from soda and chips.
Here's what the three scores mean in everyday terms:
Downside Risk 4/10 (fairly low, but not zero). The stock is calm and doesn't swing much, and the company is rock-solid — but it carries a fair amount of debt and has already dropped meaningfully from its high.
Growth Quality 5/10 (middling). Very profitable and durable, but growing slowly — not a grower.
Exponential Potential 2/10 (low). It's already huge and growing slower each year, so don't expect it to double any time soon.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLP (sector)), set to 100 a year ago
Solid = PEP · dashed = S&P 500 · dotted = XLP (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$144.22
Market cap$197B
P/E trailing6×
P/E FY26E / FY27E17× / 16×
EV / Sales2.5×
EV / EBITDA14.7×
Gross margin54.1%
Net margin9.2%
Dividend yield3.99%
Beta0.359
52-wk range$134 – $170
RSI(14)51
50 / 200-DMA$147 / $150
12-mo return+7% (SPY +21%)
Street target$167 ($142–$191)
Analyst grades15 Buy · 28 Hold · 1 Sell
FMP ratingB
Next earnings2026-08-05
What the experts actually said 0 traceable claims on PEP · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
PepsiCo, Inc. (Nasdaq: PEP) is a ~127-year-old global food-and-beverage giant — roughly a 50/50 blend of convenient foods (snacks) and beverages. Its brand portfolio includes Pepsi, Mountain Dew, Gatorade, Lay's, Doritos, Cheetos, Ruffles, Tostitos, Quaker, Tropicana (partial), Rockstar, and SodaStream. Fiscal year ends late December. CEO Ramon Laguarta; ~319,000 employees; HQ Purchase, NY.
Revenue mix (FY2025, from filings — note PepsiCo re-segmented in FY25):
By reported segment (FY25): PepsiCo Beverages North America $28.2B · PepsiCo Foods North America $27.5B · Africa/Middle East/South Asia $18.0B · Latin America $10.5B · International Beverage Franchise $5.0B · Asia Pacific/ANZ/China $4.6B. (The FY25 segment labels differ from prior years — FY24 still showed Frito-Lay NA $24.8B, PBNA $27.8B, Quaker $2.7B, Europe $13.9B — so year-over-year segment comparisons are noisy.)
By geography (FY25): United States $52.2B (~56%) · Mexico $6.9B · Russia $4.8B · Canada $3.7B · China $2.6B · UK $2.1B · Brazil/South Africa ~$1.8B each · all other $17.9B. Majority-US, but genuinely global.
Total FY25 revenue $93.9B. The strategic question the numbers pose: this is a mature, low-growth staple whose two biggest categories — sugary drinks and salty snacks — sit squarely in the crosshairs of the GLP-1 / health-and-wellness shift.
2. The expert thesis (traceable)
There is no expert coverage of PepsiCo in the Synthos knowledge base.total_claims = 0, net_bullish_voices = 0. No analyst, podcast, or investor voice in our tracked panel has made a distilled, claim-ID-reconciled statement on PEP.
That means this verdict is entirely fundamentals- and quant-driven — built from the FMP financials, analyst estimates, and price/technical data, not from any conviction panel. We will not manufacture a thesis we cannot cite. When high-quality expert claims on PEP enter the KB, this note will be re-scored; until then, treat the absence of conviction as itself a (neutral) signal: PEP is not a name our tracked voices are excited about, in either direction.
For external context only (not Synthos conviction), the sell-side is lukewarm: Hold consensus, 1 Strong Buy / 15 Buy / 28 Hold / 1 Sell.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
4 · Low-Moderate
Beta 0.36 and a defensive staple with a covered ~4% dividend cushion the downside; offset by 2.6× net-debt/EBITDA, an already-realized ~26% peak drawdown, and GLP-1/soda secular headwinds.
Growth Quality
5 · Moderate
Elite ROE (44%) and ROIC (13%) and a durable brand moat, but only ~4% forward core-EPS CAGR, FY25 GAAP EPS fell, and EBITDA margins softened — quality without growth.
Exponential Potential
2 · Low
A $197B mature mega-cap decelerating toward low-single-digit growth in shrinking-relevance categories. No credible path to a multibagger.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities. Note: FMP analyst EPS estimates are "core" (non-GAAP) EPS (~$8.11 FY25E vs $6.03 GAAP actual), so forward P/E multiples below are on the core basis the Street quotes.
Case
Key assumptions
Fair value
Bull
Snack volumes stabilize, productivity program lifts margins, international keeps compounding; FY27E core EPS beats to ~$9.6 (vs $9.06 cons); multiple re-rates to a staple-premium ~19×.
~$182 (+26%)
Base(our anchor)
Estimates roughly hit — FY27E core EPS $9.06; a slow-growth staple earns a ~17.5× multiple (below its historic ~20× as growth fades).
~$159 (+10%)
Bear
GLP-1/health shift bites snack & soda volumes, N.A. beverages stay soft, FX drags; FY27E core EPS misses to ~$8.4; multiple de-rates to ~15×.
~$126 (−13%)
Synthos fair value = the base case, ~$159 (+10%), with the full $126–$182 span as the honest range. This anchor sits below the Street's $167.2 consensus — we are less willing than the sell-side to underwrite a re-rate given the growth fade. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). PEP is a mature compounder well past any acceleration — the opposite of an exponential:
Acceleration (the 2nd derivative) is flat-to-negative: FY25 revenue grew only +2.3% and GAAP EPS declined ($6.98 → $6.03). There is no inflection to point to; the estimate curve is a gentle, decelerating slope.
Room to run: at $197B in a mature ~$1T+ global food-and-beverage category it already dominates, there is no market-cap "room" for a multibagger; a 3× from here implies a ~$590B staple, which the category math does not support.
Reinvestment runway: limited — capex is only ~4.5% of revenue, and capital is returned via a ~4% dividend (88% GAAP payout) rather than reinvested at high incremental returns.
Exponential Potential: Low (2/10). Own PEP, if at all, for income and defensiveness — not for growth and certainly not for a multibagger. This is structurally a Watch/hold-for-yield name, not a flagship exponential.
Revenue: FY25 $93.9B, +2.3% (FY24 $91.85B, +0.4% on FY23 $91.47B). Flat-lining top line.
Quarterly trajectory: Q1'25 $17.92B → Q2 $22.73B → Q3 $23.94B → Q4 $29.34B → Q1'26 $19.44B (+8.5% YoY vs Q1'25) — the Q1'26 uptick is the one recent bright spot.
Margins: gross 54.1% TTM, operating ~14.8%, EBITDA 17.1% TTM (down from ~18% in FY24), net 9.2% TTM. Gross margin is healthy; profitability trend is soft.
Earnings: GAAP net income $8.24B FY25, down from $9.58B FY24; GAAP EPS $6.03 (diluted $6.00) vs $6.98. Core (non-GAAP) EPS runs materially higher (~$8.11 FY25E) — the gap is restructuring, mark-to-market, and amortization. We anchor risk on GAAP and value on the Street's core basis, and flag the gap explicitly.
Cash flow: operating CF $12.09B, capex −$4.42B, FCF $7.67B FY25 (FCF yield ~4.5%). Solid and stable, but FCF only ~covers the $7.64B dividend + buyback — the payout is tight.
Balance sheet: total debt $49.9B, net debt $40.7B, net-debt/EBITDA ~2.6× — investment-grade and serviceable (interest coverage ~12×), but meaningfully levered for a staple. Current ratio 0.90 (typical for the model, given fast payables).
6. Valuation — priced in or room?
PEP is roughly fairly valued, arguably slightly cheap relative to its own history but not versus its growth. Trailing 22.6× GAAP EPS, 14.7× EV/EBITDA, 2.5× EV/sales; on the Street's core-EPS basis the forward multiple is 16.7× (FY26E) → 15.9× (FY27E) → 13.9× (FY30E). That is a discount to PEP's historical ~20–22× core multiple — the market is already docking it for slow growth. The FMP letter rating is B (overall score 3/5), dinged on debt-to-equity (1/5) and P/E (2/5), helped by ROE (5/5). A reverse read: at $144, the market prices in ~mid-single-digit EPS growth and no re-rate — a low bar PEP can likely clear, which is what limits downside. Street targets (context): consensus $167.2, high $191, low $142. Our $159 base FV is below consensus because we don't underwrite the multiple re-rate the sell-side implies. Not a value trap, not a bargain — a fair-price staple.
7. Technicals (computed from the tech block)
Trend:down. $144.22 sits below both the 50-DMA ($147.4) and 200-DMA ($150.1), and the 50 is below the 200 (death-cross posture). MACD −1.83 (negative).
Location:−15.4% off the 52-week high ($170.49), only +7.8% off the 52-week low ($133.81); max drawdown −26.5% from peak — a real, sizeable correction already absorbed.
Momentum: RSI(14) 50.8 — dead neutral; neither oversold nor overbought.
Relative strength (the tell): PEP +6.6% 12-mo vs SPY +20.6% and QQQ +30.3%; −6.7% 3-mo vs SPY +13.7%. Persistent, broad underperformance — the market has been paying up for growth elsewhere.
Read: technicals confirm the fundamental story — a de-rated, out-of-favor staple in a downtrend. No momentum reason to chase; a defensive buyer might use the ~$134 52-week-low area / a reclaim of the 200-DMA as reference points. This is a "wait for a base" chart, consistent with the Watch verdict.
8. Moat & competitive position
PepsiCo's moat is real and durable: (1) iconic brands with a century of equity (Pepsi, Lay's, Doritos, Gatorade, Quaker); (2) an unmatched direct-store-delivery (DSD) distribution system — a genuine barrier in snacks; (3) scale in procurement, manufacturing, and shelf presence. The result is elite economics — ROE 44%, ROIC 13%, gross margin 54%. The vulnerability is not competitive share loss but category relevance: sugary beverages and salty snacks face the GLP-1 appetite-suppression wave, sugar/health regulation, and a durable consumer wellness shift. Frito-Lay's snack moat is the crown jewel and the most defensible piece; N.A. beverages is the softer flank.
Peer set (market cap): Coca-Cola $362B (the classic comp), Philip Morris $284B, Anheuser-Busch InBev $157B, Unilever $135B, British American Tobacco $134B, Monster Beverage $95B, Coca-Cola Europacific Partners $47B, Keurig Dr Pepper $45B, Coca-Cola FEMSA $23B, Coca-Cola Consolidated $15B. Versus KO, PEP has the snack-diversification edge but the weaker recent beverage momentum and higher leverage; it trades at a discount to KO on most multiples.
9. Management, capital allocation & guidance
Capital allocation: dividend-first — $7.64B dividends FY25 (~88% of GAAP EPS, ~4% yield) plus a modest ~$1B buyback, against $7.67B FCF. The payout is well-covered on core earnings but tight on GAAP; this is a return-of-capital story, not a reinvestment story. ~$4.4B capex (~4.5% of sales) funds maintenance and productivity, not expansion.
Insider activity: mixed and routine. Recent officer sales (International Beverages CEO E. Willemsen sold ~6,500 shares at ~$164 in March 2026) alongside routine director stock awards (2026-07-02) and a large director acquisition (R. Pohlad, 900,000 shares via other/gift transfer, non-open-market). No alarming cluster of discretionary open-market selling in the sampled window.
Guidance: PepsiCo's own earnings-call guidance is not in the Synthos KB (no management voice ingested for PEP). Watch the 2026-07-09 print for updated full-year organic-revenue and core-EPS guidance. Gap flagged: management guidance and analyst Q&A are not yet captured for PEP.
10. Catalysts & what to watch
Next earnings: 2026-07-09 (Q2'26; Street EPS $2.19, revenue ~$23.96B). Key lines: North America beverage & Frito-Lay volume trends and any organic-revenue guidance change.
Snack/soda volume vs the GLP-1 wave: the single most important multi-quarter tell — are core categories stabilizing or eroding?
Productivity / margin program: whether cost actions restore the EBITDA margin that slipped in FY25.
FX: ~44% of revenue is ex-US (Mexico, Russia, LatAm) — a dollar swing moves reported results.
Dividend: PEP is a Dividend King; continuation of increases is a support level for the shares.
Thesis tripwires (what would change the call): two-plus quarters of accelerating snack-volume declines (→ Avoid); a dividend-growth pause or a payout squeeze above ~100% of FCF (→ Avoid); or, conversely, a return to mid-single-digit organic growth + margin recovery (→ Buy — Tactical).
11. Key risks
GLP-1 / health secular shift (structural): appetite-suppressant drugs and the wellness trend directly threaten sugary drinks and salty snacks — PepsiCo's two core categories. This is the defining long-term risk and the reason growth may stay slow.
Growth stall / de-rating: FY25 revenue +2% and GAAP EPS down — if the slow-growth narrative hardens, the multiple can compress further.
Leverage: 2.6× net-debt/EBITDA is meaningful for a staple; higher-for-longer rates raise refinancing cost and pressure the tight dividend cover.
FX & emerging-market exposure: Mexico, Russia, LatAm, and other non-US markets (~44% of sales) add currency and geopolitical volatility.
Input-cost / pricing fatigue: consumers have pushed back on price increases; further pricing power is limited, so volume must do the work.
No expert conviction: unlike our flagship names, there is zero tracked-panel support — the bull case rests only on quality and yield, not on differentiated insight.
12. Verdict, position sizing & monitoring
Watch. PepsiCo is a genuinely high-quality, low-volatility staple (44% ROE, 54% gross margin, ~$7.7B FCF, ~4% dividend, beta 0.36) trading at a fair-to-slightly-cheap ~16× forward core earnings — but it grew revenue only ~2% and saw GAAP EPS fall in FY25, it has underperformed the market by ~14 points over 12 months, it faces a real GLP-1/health secular headwind, and it carries zero Synthos expert conviction. There is no catalyst to justify a growth allocation and no bargain to justify a deep-value one. It is a hold-for-income name, not a buy-with-conviction one.
Sizing: if held at all, income/defensive ballast, ~1–2% — a low-beta yield sleeve position, not a growth or flagship allocation. Prospective buyers can reasonably wait for a base near the ~$134 low or a reclaim of the 200-DMA.
Monitoring: re-underwrite on the §10 tripwires; formal re-score at the 2026-07-09 print and whenever expert claims enter the KB. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $144.22.
Single biggest risk: the GLP-1 / health-and-wellness shift slowly eroding demand for core snacks and sugary beverages.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — PepsiCo has no expert coverage in the Synthos knowledge base. This note is explicitly fundamentals- and quant-driven; no conviction is claimed or fabricated. Fabricated conviction is structurally impossible (claim-ID reconciliation), and here there are simply no claims to cite.
Data as-of: fundamentals 2026-03-21 (Q1'26) · estimates & prices 2026-07-02/03. Forward figures are analyst consensus (FMP) and are core (non-GAAP) EPS, labeled as estimates; GAAP EPS is materially lower.
Segment caveat: PepsiCo re-segmented in FY25, so year-over-year segment splits are not clean comparisons.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").